国际脊柱关节炎评估协会(ASAS)基于共识的难治性及治疗抵抗性中轴型脊柱关节炎专家定义
ASAS通过2022年文献综述及2022至2023年两轮德尔菲共识流程制定难治性中轴型脊柱关节炎(D2M axSpA)专家定义,涵盖治疗失败、疾病控制欠佳及医患双方均认可存在问题的症状/体征,该定义包含治疗抵抗(TR)疾病,并于2024年1月获ASAS成员89%(109/123)投票赞成通过。
要点
- D2M axSpA定义涵盖治疗失败、疾病控制欠佳及医患认可的问题性症状/体征。
- 治疗失败指按ASAS-EULAR推荐治疗且≥2种不同作用机制生物或靶向合成DMARDs失败(除非有禁忌)。
- TR axSpA被D2M定义涵盖,但需治疗失败史、客观炎症活动证据并排除非炎症性无应答原因。
核心结论
- ASAS的D2M axSpA定义(含TR疾病)可识别需求未满足的患者,为进一步研究及改善临床照护铺路。
研究设计与样本
- 2022年进行文献综述以识别既往D2M/TR axSpA的潜在定义,随后于2022至2023年开展两轮德尔菲共识流程以确定D2M axSpA的组成要素。
- 基于德尔菲流程结果起草D2M axSpA定义,提交给包含患者代表的专家工作组,随后于2024年1月提交ASAS成员进行背书。
主要发现
- 共识达成D2M定义,涵盖治疗失败、疾病控制欠佳及医患双方均认可存在问题的症状/体征,适用于由风湿科医生诊断为axSpA的患者。
- 该定义代表一个宽泛概念,包含导致治疗结果不满意的各种原因。
- TR axSpA被D2M定义涵盖,但需治疗失败史、存在客观炎症活动证据并排除非炎症性无应答原因。
- 拟议的含TR疾病的D2M定义于2024年1月ASAS年会上获背书,89%(109/123)投票赞成。
关键数值与推荐
- 治疗失败定义为按ASAS-EULAR推荐治疗且≥2种不同作用机制生物或靶向合成DMARDs失败(除非有禁忌)。
- TR axSpA需治疗失败史、客观炎症活动证据并排除非炎症性无应答原因。
- D2M定义于2024年1月获ASAS成员89%(109/123)投票赞成通过。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop a consensus-based expert definition of difficult-to-manage (D2M) axial spondyloarthritis (axSpA), incorporating treatment-refractory (TR) disease. METHODS: A literature review was conducted in 2022 to identify potential definitions for D2M/TR axSpA from prior studies, followed by a 2-round Delphi consensus process conducted in 2022 and 2023 to identify components of D2M axSpA. Based on the results of the Delphi process, a draft of the D2M axSpA definition was developed and presented to the expert task force, including patient representation, and, subsequently, to the Assessment of SpondyloArthritis International Society (ASAS) membership for endorsement in January 2024. RESULTS: Consensus was reached on a D2M definition encapsulating treatment failure (treatment according to the ASAS-European Alliance of Associations for Rheumatology recommendations and failure of ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action unless contraindicated), suboptimal disease control, and physician or patient acknowledgement of problematic signs/symptoms in patients diagnosed with axSpA by the rheumatologist. This definition represents a broad concept that includes various reasons that lead to an unsatisfactory treatment outcome. TR axSpA is covered by the D2M definition but requires a history of treatment failure, the presence of objective signs of inflammatory activity, and the exclusion of noninflammatory reasons for nonresponse. The proposed D2M definition incorporating TR disease was endorsed by ASAS at the annual meeting in January 2024, with 89% votes (109/123) in favour of it. CONCLUSIONS: The ASAS D2M axSpA definition, including TR disease, allows for identifying patients with unmet needs, paving the way for further research in this condition and its clinical care improvement.
引用
- Poddubnyy D, Navarro-Compán V, Torgutalp M, et al. The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis. Ann Rheum Dis. 2025. PMID: 39955166. doi:10.1016/j.ard.2025.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。